Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment

Thomas A Burley, Justyna Mączyńska, Anant Shah, Wojciech Szopa, Kevin J Harrington, Jessica K R Boult, Anna Mrozek-Wilczkiewicz, Maria Vinci, Jeffrey C Bamber, Wojciech Kaspera, Gabriela Kramer-Marek

Research output: Contribution to journalArticle

Abstract

Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (ZEGFR:03115 ) was conjugated to the phthalocyanine dye, IR700DX, which when excited with near-infrared light produces a cytotoxic response. ZEGFR:03115 -IR700DX EGFR-specific binding was confirmed by flow cytometry and confocal microscopy. The conjugate showed effective targeting of EGFR positive GBM cells in the brain. The therapeutic potential of the conjugate was assessed both in vitro, in GBM cell lines and spheroids by the CellTiter-Glo® assay, and in vivo using subcutaneous U87-MGvIII xenografts. In addition, mice were imaged pre- and post-PIT using the IVIS/Spectrum/CT to monitor treatment response. Binding of the conjugate correlated to the level of EGFR expression in GBM cell lines. The cell proliferation assay revealed a receptor-dependent response between the tested cell lines. Inhibition of EGFRvIII+ve tumor growth was observed following administration of the immunoconjugate and irradiation. Importantly, this response was not seen in control tumors. In conclusion, the ZEGFR:03115 -IR700DX showed specific uptake in vitro and enabled imaging of EGFR expression in the orthotopic brain tumor model. Moreover, the proof-of-concept in vivo PIT study demonstrated therapeutic efficacy of the conjugate in subcutaneous glioma xenografts.

Original languageEnglish
Pages (from-to)2363-2374
Number of pages12
JournalInternational Journal of Cancer
Volume142
Issue number11
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Glioblastoma
Epidermal Growth Factor Receptor
Heterografts
Brain Neoplasms
Cell Line
Therapeutics
Immunoconjugates
Neoplasms
Sequence Deletion
Photochemotherapy
Missense Mutation
Confocal Microscopy
Glioma
Immunotherapy
Flow Cytometry
Coloring Agents
Cell Proliferation
Light
Brain
Growth

Cite this

Burley, T. A., Mączyńska, J., Shah, A., Szopa, W., Harrington, K. J., Boult, J. K. R., ... Kramer-Marek, G. (2018). Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. International Journal of Cancer, 142(11), 2363-2374. https://doi.org/10.1002/ijc.31246

Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. / Burley, Thomas A; Mączyńska, Justyna; Shah, Anant; Szopa, Wojciech; Harrington, Kevin J; Boult, Jessica K R; Mrozek-Wilczkiewicz, Anna; Vinci, Maria; Bamber, Jeffrey C; Kaspera, Wojciech; Kramer-Marek, Gabriela.

In: International Journal of Cancer, Vol. 142, No. 11, 01.06.2018, p. 2363-2374.

Research output: Contribution to journalArticle

Burley, TA, Mączyńska, J, Shah, A, Szopa, W, Harrington, KJ, Boult, JKR, Mrozek-Wilczkiewicz, A, Vinci, M, Bamber, JC, Kaspera, W & Kramer-Marek, G 2018, 'Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment', International Journal of Cancer, vol. 142, no. 11, pp. 2363-2374. https://doi.org/10.1002/ijc.31246
Burley TA, Mączyńska J, Shah A, Szopa W, Harrington KJ, Boult JKR et al. Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. International Journal of Cancer. 2018 Jun 1;142(11):2363-2374. https://doi.org/10.1002/ijc.31246
Burley, Thomas A ; Mączyńska, Justyna ; Shah, Anant ; Szopa, Wojciech ; Harrington, Kevin J ; Boult, Jessica K R ; Mrozek-Wilczkiewicz, Anna ; Vinci, Maria ; Bamber, Jeffrey C ; Kaspera, Wojciech ; Kramer-Marek, Gabriela. / Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. In: International Journal of Cancer. 2018 ; Vol. 142, No. 11. pp. 2363-2374.
@article{ebfc43c95bda4c44829f839388575f0b,
title = "Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment",
abstract = "Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (ZEGFR:03115 ) was conjugated to the phthalocyanine dye, IR700DX, which when excited with near-infrared light produces a cytotoxic response. ZEGFR:03115 -IR700DX EGFR-specific binding was confirmed by flow cytometry and confocal microscopy. The conjugate showed effective targeting of EGFR positive GBM cells in the brain. The therapeutic potential of the conjugate was assessed both in vitro, in GBM cell lines and spheroids by the CellTiter-Glo{\circledR} assay, and in vivo using subcutaneous U87-MGvIII xenografts. In addition, mice were imaged pre- and post-PIT using the IVIS/Spectrum/CT to monitor treatment response. Binding of the conjugate correlated to the level of EGFR expression in GBM cell lines. The cell proliferation assay revealed a receptor-dependent response between the tested cell lines. Inhibition of EGFRvIII+ve tumor growth was observed following administration of the immunoconjugate and irradiation. Importantly, this response was not seen in control tumors. In conclusion, the ZEGFR:03115 -IR700DX showed specific uptake in vitro and enabled imaging of EGFR expression in the orthotopic brain tumor model. Moreover, the proof-of-concept in vivo PIT study demonstrated therapeutic efficacy of the conjugate in subcutaneous glioma xenografts.",
author = "Burley, {Thomas A} and Justyna Mączyńska and Anant Shah and Wojciech Szopa and Harrington, {Kevin J} and Boult, {Jessica K R} and Anna Mrozek-Wilczkiewicz and Maria Vinci and Bamber, {Jeffrey C} and Wojciech Kaspera and Gabriela Kramer-Marek",
note = "{\circledC} 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/ijc.31246",
language = "English",
volume = "142",
pages = "2363--2374",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment

AU - Burley, Thomas A

AU - Mączyńska, Justyna

AU - Shah, Anant

AU - Szopa, Wojciech

AU - Harrington, Kevin J

AU - Boult, Jessica K R

AU - Mrozek-Wilczkiewicz, Anna

AU - Vinci, Maria

AU - Bamber, Jeffrey C

AU - Kaspera, Wojciech

AU - Kramer-Marek, Gabriela

N1 - © 2018 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (ZEGFR:03115 ) was conjugated to the phthalocyanine dye, IR700DX, which when excited with near-infrared light produces a cytotoxic response. ZEGFR:03115 -IR700DX EGFR-specific binding was confirmed by flow cytometry and confocal microscopy. The conjugate showed effective targeting of EGFR positive GBM cells in the brain. The therapeutic potential of the conjugate was assessed both in vitro, in GBM cell lines and spheroids by the CellTiter-Glo® assay, and in vivo using subcutaneous U87-MGvIII xenografts. In addition, mice were imaged pre- and post-PIT using the IVIS/Spectrum/CT to monitor treatment response. Binding of the conjugate correlated to the level of EGFR expression in GBM cell lines. The cell proliferation assay revealed a receptor-dependent response between the tested cell lines. Inhibition of EGFRvIII+ve tumor growth was observed following administration of the immunoconjugate and irradiation. Importantly, this response was not seen in control tumors. In conclusion, the ZEGFR:03115 -IR700DX showed specific uptake in vitro and enabled imaging of EGFR expression in the orthotopic brain tumor model. Moreover, the proof-of-concept in vivo PIT study demonstrated therapeutic efficacy of the conjugate in subcutaneous glioma xenografts.

AB - Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just 12-15 months following standard therapy. A combination of interventions targeting tumor-specific cell surface regulators along with convergent downstream signaling pathways may enhance treatment efficacy. Against this background, we investigated a novel photoimmunotherapy approach combining the cytotoxicity of photodynamic therapy with the specificity of immunotherapy. An EGFR-specific affibody (ZEGFR:03115 ) was conjugated to the phthalocyanine dye, IR700DX, which when excited with near-infrared light produces a cytotoxic response. ZEGFR:03115 -IR700DX EGFR-specific binding was confirmed by flow cytometry and confocal microscopy. The conjugate showed effective targeting of EGFR positive GBM cells in the brain. The therapeutic potential of the conjugate was assessed both in vitro, in GBM cell lines and spheroids by the CellTiter-Glo® assay, and in vivo using subcutaneous U87-MGvIII xenografts. In addition, mice were imaged pre- and post-PIT using the IVIS/Spectrum/CT to monitor treatment response. Binding of the conjugate correlated to the level of EGFR expression in GBM cell lines. The cell proliferation assay revealed a receptor-dependent response between the tested cell lines. Inhibition of EGFRvIII+ve tumor growth was observed following administration of the immunoconjugate and irradiation. Importantly, this response was not seen in control tumors. In conclusion, the ZEGFR:03115 -IR700DX showed specific uptake in vitro and enabled imaging of EGFR expression in the orthotopic brain tumor model. Moreover, the proof-of-concept in vivo PIT study demonstrated therapeutic efficacy of the conjugate in subcutaneous glioma xenografts.

U2 - 10.1002/ijc.31246

DO - 10.1002/ijc.31246

M3 - Article

C2 - 29313975

VL - 142

SP - 2363

EP - 2374

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 11

ER -